<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nuwellis Inc — News on 6ix</title>
<link>https://6ix.com/company/nuwellis-inc</link>
<description>Latest news and press releases for Nuwellis Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nuwellis-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a42078dffbe2df10a859.webp</url>
<title>Nuwellis Inc</title>
<link>https://6ix.com/company/nuwellis-inc</link>
</image>
<item>
<title>Nuwellis Highlights Case Study Featuring Precision Ultrafiltration Therapy in Pediatric Cardiorenal Care at ISHLT 2026 Annual Meeting</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-highlights-case-study-featuring-precision-ultrafiltration-therapy-in-pediatric-cardiorenal-care-at-ishlt-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-highlights-case-study-featuring-precision-ultrafiltration-therapy-in-pediatric-cardiorenal-care-at-ishlt-2026-annual-meeting</guid>
<pubDate>Wed, 29 Apr 2026 12:30:00 GMT</pubDate>
<description>Poster presentation showcased continued advancement of Aquadex therapy in pediatric applications, underscoring continued need for adoption in fluid management in pediatric heart failureMINNEAPOLIS, April 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights a case study presented by the University of Iowa Stead Family Children's Hospital at the 46th Annual Meeting & Scientifi</description>
</item>
<item>
<title>Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-to-participate-in-the-aats-106th-annual-meeting-and-eras-cardiac-spring-retreat</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-to-participate-in-the-aats-106th-annual-meeting-and-eras-cardiac-spring-retreat</guid>
<pubDate>Thu, 23 Apr 2026 12:30:00 GMT</pubDate>
<description>Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth 530MINNEAPOLIS, April 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will participate in the AATS 106th Annual Meeting taking place May 2–5 in Chicago. The Company will be showcasing its Aquadex SmartFlow® ultrafiltration system for fluid removal at Booth 530. At the sta</description>
</item>
<item>
<title>Nuwellis Announces Aquadex Software Update</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-announces-aquadex-software-update</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-announces-aquadex-software-update</guid>
<pubDate>Tue, 21 Apr 2026 12:30:00 GMT</pubDate>
<description>New release enhances usability and delivers more precise fluid management for pediatric patientsMINNEAPOLIS, April 21, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on solutions for patients with cardiorenal conditions, today announced a software update to its Aquadex SmartFlow® ultrafiltration platform. The update is designed to improve usability, streamline clinical workflow, and enhance overall user experience. A key feature of the release is a m</description>
</item>
<item>
<title>Nuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical Momentum</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-welcomes-back-three-former-team-members-to-accelerate-commercial-and-clinical-momentum</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-welcomes-back-three-former-team-members-to-accelerate-commercial-and-clinical-momentum</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>MINNEAPOLIS, April 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients</description>
</item>
<item>
<title>Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-engages-core-ir-for-public-relations-shareholder-communications-and-social-media-management-services</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-engages-core-ir-for-public-relations-shareholder-communications-and-social-media-management-services</guid>
<pubDate>Thu, 09 Apr 2026 12:30:00 GMT</pubDate>
<description>MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has retained CORE IR, a leading investor relations, public relations, and strategic advisory firm, to assist the Company with public relations, shareholder communications, and social media management services. Nuwellis Chairman and CEO John Erb commented, “We believe CORE IR’s integrated communications</description>
</item>
<item>
<title>Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-strengthens-commercial-infrastructure-with-new-south-texas-territory</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-strengthens-commercial-infrastructure-with-new-south-texas-territory</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Strategic expansion of field coverage enhances hospital engagement and increases access to Aquadex® therapy across the region MINNEAPOLIS, April 07, 2026</description>
</item>
<item>
<title>Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-pediatric-category-achieves-approximately-50percent-of-total-us-revenue-in-2025-marking-growth-milestone</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-pediatric-category-achieves-approximately-50percent-of-total-us-revenue-in-2025-marking-growth-milestone</guid>
<pubDate>Tue, 31 Mar 2026 12:30:00 GMT</pubDate>
<description>Pediatric footprint expands to 47 centers nationwide, including six of the nation’s top 10 children’s hospitalsMINNEAPOLIS, March 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces continued momentum in its pediatric category, which is now the Company’s largest and fastest-growing category and represents approximately 50% of total U.S. revenue. “Our pediatric category has b</description>
</item>
<item>
<title>Nuwellis Completes Acquisition of Rendiatech</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-completes-acquisition-of-rendiatech</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-completes-acquisition-of-rendiatech</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Adds automated kidney function monitoring technology to support earlier clinical insight and strengthen Nuwellis’ fluid management platform MINNEAPOLIS, March</description>
</item>
<item>
<title>Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-inc-announces-fourth-quarter-and-full-year-2025-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-inc-announces-fourth-quarter-and-full-year-2025-financial-results-1</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients</description>
</item>
<item>
<title>Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-appoints-dr-stuart-l-goldstein-as-director-of-clinical-strategy-to-advance-pediatric-and-cardiorenal-strategy-7</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-appoints-dr-stuart-l-goldstein-as-director-of-clinical-strategy-to-advance-pediatric-and-cardiorenal-strategy-7</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Appointment Strengthens Clinical Leadership in Precision Fluid Management and Acute Kidney Injury MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis,</description>
</item>
<item>
<title>Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-appoints-david-a-mcdonald-and-martin-j-emerson-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-appoints-david-a-mcdonald-and-martin-j-emerson-to-board-of-directors</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with</description>
</item>
<item>
<title>Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-10-2026</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-10-2026</guid>
<pubDate>Tue, 24 Feb 2026 13:00:00 GMT</pubDate>
<description>MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the</description>
</item>
<item>
<title>Nuwellis Appoints Carisa Schultz as Chief Financial Officer</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-appoints-carisa-schultz-chief-130000653</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-appoints-carisa-schultz-chief-130000653</guid>
<pubDate>Fri, 30 Jan 2026 13:00:00 GMT</pubDate>
<description>Schultz brings public company healthcare finance and medical technology experience to support Nuwellis’ next phase of growthMINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as</description>
</item>
<item>
<title>Nuwellis Announces $5 Million Private Placement and Warrant Inducement Transaction, Priced At-The-Market</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-announces-5-million-private-213600066</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-announces-5-million-private-213600066</guid>
<pubDate>Thu, 29 Jan 2026 21:36:00 GMT</pubDate>
<description>MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered into a securities purchase agreement with an institutional and accredited investor (the “Investor”) for the purchase and sale of 994,537 shares (the “Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”) or (pre-funded warrants</description>
</item>
<item>
<title>Nuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advancing Its Cardiorenal Portfolio Strategy</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-enters-definitive-agreement-acquire-213500311</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-enters-definitive-agreement-acquire-213500311</guid>
<pubDate>Thu, 29 Jan 2026 21:35:00 GMT</pubDate>
<description>Transaction positions Nuwellis to expand into real-time kidney function monitoring and strengthen its long-term cardiorenal platform, subject to customary closing conditionsMINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered into a Securities Purchase Agreement to acquire all of the issued and outstanding capital stock of Rendiatech</description>
</item>
<item>
<title>Nuwellis Announces Changes to Board of Directors</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-announces-changes-board-directors-214000377</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-announces-changes-board-directors-214000377</guid>
<pubDate>Fri, 23 Jan 2026 21:40:00 GMT</pubDate>
<description>MINNEAPOLIS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced the appointment of Katharyn Field and Mika Grasso to its board of directors, effective January 21, 2026. Ms. Field is the Chief Executive Officer of ISpecimen Inc., where she oversees performance improvement and the redevelopment of the proprietary software platform. Prior to serving as Chief Executiv</description>
</item>
<item>
<title>Nuwellis Announces Issuance of New U.S. Patent Supporting Advanced Safety Design for Pediatric Extracorporeal Therapy</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-announces-issuance-u-patent-131500137</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-announces-issuance-u-patent-131500137</guid>
<pubDate>Tue, 06 Jan 2026 13:15:00 GMT</pubDate>
<description>Patent issuance strengthens pediatric intellectual property portfolio and advances system-level safety designMINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company advancing precision fluid management technologies across the cardio-renal continuum today announced that the United States Patent and Trademark Office recently issued a new U.S. patent covering advanced safety mechanisms for blood return line clamps used in extracorporeal blood filtr</description>
</item>
<item>
<title>Lenox Hill Hospital Study Highlights the Broad Utility of Aquadex in Managing Fluid Overload Across Critical Care Settings</title>
<link>https://6ix.com/company/nuwellis-inc/news/lenox-hill-hospital-study-highlights-131500891</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/lenox-hill-hospital-study-highlights-131500891</guid>
<pubDate>Tue, 09 Dec 2025 13:15:00 GMT</pubDate>
<description>Findings reinforce Nuwellis’ leadership in precision ultrafiltration for patients with acute kidney injury and fluid overload.MINNEAPOLIS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the critical interplay between the heart and kidneys, today announced the presentation of new real-world data from New York City’s Lenox Hill Hospital at the 2025 American Society</description>
</item>
<item>
<title>Nuwellis Continues Clinician-Driven Growth in Pediatric Care with a Leading Hospital in the Northeast U.S.</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-continues-clinician-driven-growth-131500108</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-continues-clinician-driven-growth-131500108</guid>
<pubDate>Thu, 04 Dec 2025 13:15:00 GMT</pubDate>
<description>Pediatric nephrology and cardiology teams continue to seek out Aquadex for safe, precise fluid management in complex casesMINNEAPOLIS, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, announced today that a leading Northeastern U.S. children’s hospital has initiated an Aquadex Ultrafiltration Program. Pediatric nephrology and cardiology teams across the country continue to se</description>
</item>
<item>
<title>Nuwellis Reports Third Quarter 2025 Results and Continued Operational Momentum</title>
<link>https://6ix.com/company/nuwellis-inc/news/nuwellis-reports-third-quarter-2025-131500703</link>
<guid isPermaLink="true">https://6ix.com/company/nuwellis-inc/news/nuwellis-reports-third-quarter-2025-131500703</guid>
<pubDate>Wed, 12 Nov 2025 13:15:00 GMT</pubDate>
<description>Company delivers steady performance and achieves key milestones across critical care, pediatrics, and hospital-based outpatient therapyMINNEAPOLIS, MN, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the critical interplay between the heart and kidneys, today reported financial results for the third quarter ended September 30, 2025 and provided a business update on</description>
</item>
</channel>
</rss>